Today we have the uncertain pleasure of checking out a teaser pitch from James Altucher, who one of our readers referred to as the “white Don King of the stock gurus” — he’s peddling subscriptions to Altucher’s Investment Network (that’s his “entry level” letter, $79/year), and the bait he dangles out is his “special report” […]
Articles
- Most Relevant
- Most Recent
Yesterday I started out with a look at George Leong’s “Hidden Stock #1” from the teaser ad for his Pennies to Millions newsletter — today, as promised, I’m following up with the other two stocks he pitched. These are being hinted at for us as “home run” and “triple digit” opportunities — with the intro […]
Braden Copeland used to work for Porter Stansberry, co-editing his Stansberry’s Investment Advisory and working on Inside Strategist (since shuttered) that picked stocks based on insider buying. Earlier this year, he moved down the street to a different Agora-affiliated office to work for Bill Bonner’s son, Will, at Bonner & Partners and launch a newsletter […]
I usually have fun looking at Jeff Opdyke’s teasers — he writes the Sovereign Individual letter for the Sovereign Society, and he often picks up on little foreign stocks that pique my interest (as you’ve probably noted, I have a soft spot in my heart for obscure stuff that’s sometimes hard to trade — it’s […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]
The plan was for Doc Gumshoe to fix his gaze on the hype around Delta 8 as the ultimate banned cancer cure, which he will definitely get around to. But the volume of comments and queries that “Cancer: The Lay of the Land in 2018” was such that I have little choice but to […]
Gerardo Del Real is teasing a gold stock, as gold touches all-time highs, and talking up the potential for a 12,500% gain… that sounds quite lovely no? Maybe even the kind of thing that makes you want to pony up $199 for a subscription to a newsletter? It never makes sense to count on riches […]
Special Update on Cellceutix[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
Today we have to put my usual cautionary note up top. The stock Frank Curzio is pitching as the key supplier for “The 20-Second Battery” is ridiculously small. It has already been recommended to his subscribers over at Phase 1 Investor, so presumably they’ve gotten their fill of the stock (he also touted it about […]
Well, well, well — another month, another Phase 1 teaser from Frank Curzio and the Stansberry folks. And if you’re going to use your massive mailing list of a few million investors to sell a $3,000 newsletter that most of them won’t ever consider, well, you can pretty much predict that the queries will make […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
The Disruptors and Dominators newsletter, one of the “entry level” letters from Weiss, is out pitching a “silver bullet” company — a firm that has developed a universal cancer vaccine. And, of course, they’ll tell you all about it — for your $49 subscription fee. Here at Stock Gumshoe, we’d like you to think things […]
The ads that get the most attention tend to be either those that are most dramatically distributed, with seemingly every single email address getting multiple copies… or those that come with a big promise and a very high price. Today’s topic of interest is the latter, since we’re told that Stansberry Venture Value’s Dave Lashmet […]
Neither of the two picks that Patrick Cox has lately been teasing are new — but I’m getting a lot of questions about both of them so I thought I’d provide a couple quick answers on this lovely Friday afternoon. Both of these teaser ads are designed to encourage investors to subscribe to his Breakthrough […]
You can always count on a good story from a Phase 1 teaser — Phase 1 is the fancy top-of-the-line upgrade newsletter from Stansberry & Associates ($5,000/year, though it’s usually “on sale” for $3,000 when they’re promoting it as they are now), currently edited by Frank Curzio, and it has historically focused on lots of […]
Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]
This is a bonus weekend “quickie” for you, so it’s not a stock I’m going to go in depth on… but I thought you might want a few moments to think about it while the market’s not open. The promise is absurd, here’s a taste of it from the top of the ad: “ALERT: Agora […]
Welcome back from vacation, me! There’s no question what ad should be covered first as I brush the sand off my feet and turn up the heat here at Gumshoe HQ… it’s the pitch from Marc Lichtenfeld for his Lightning Trend Trader over at Oxford Club, and the “special report” he’s dangling as bait. That […]
We’ve seen folks ask about Manny Backus services before — he’s published a few different alert services and newsletters in the past, most of them focused, as far as I can tell, on short-term trading. We haven’t written about any of them before because he hasn’t actually teased anything very specific in terms of a […]
This article was originally published as part of the Friday File on August 10, 2018. It has not been updated or revised, though the stock teased is still at roughly the same price and no major news has hit since then. We’re breaking the Friday File up into two parts today — starting with this […]
Matt McCall’s entry level newsletter Investment Opportunities (currently $49/year) is being advertised with a promised “free” special report about the three stocks you need to own before more states legalize sports betting… perhaps as soon as September 6. What’s so special about September 6? That’s just a guess that more attention will come to this […]
Is this going to be good news, or bad news, or somewhere in between? On balance, I would say good news, simply because the research and investigation is going on at an intense pace. Currently there are 1,903 clinical trials underway at some stage, in the US and all over the world. When I first […]
When I last took a look at what was happening in the treatment of migraines, I took careful pains to elucidate the differences between migraines and a plain old bad headache – the fact that migraines affect only one side of the head, and a detailed disquisition on the symptoms that many migraineurs (that’s the […]
Crazy earnings week, eh? That leads me to a few adjustments to the portfolio, as my opinions have changed about a few stocks at the top of the Real Money Portfolio. So this week your Friday File is another run through a hodgepodge of stocks, starting with the one that I think is looking most […]
The ads that get the most attention tend to be either those that are most dramatically distributed, with seemingly every single email address getting multiple copies… or those that come with a big promise and a very high price. Today’s topic of interest is the latter, since we’re told that Stansberry Venture Value’s Dave Lashmet […]
Does anyone know if Jim Rickard’s ongoing teaser about the IMF and other global institutions developing a crypto fiat to replace the dollar has any merit or is pure fluff? If the former, what is he actually trying to tease out, is it investable and should we care? Thanks, Nils
What’s on the docket today? An ad for Jim Woods’ Successful Investing, which seems to be a newly revamped version of that longtime “entry level” investment newsletter (founded by Dick Fabian — Jim took over the Successful line of letters when Dick’s son, Doug Fabian, left the newsletter business in 2017). The letter is being […]
Richards says the global elite will blame Donald for the financial woes of the world and issue a new world currency that will devalue the dollar. As usual, Richards promises big gains if you follow his advice, by July 1st. Is he pushing gold again or is it another blockchain or cryptocurrency? What is the […]
The last time we were inundated with a junior mining promo from Nick Hodge it was about that “tiny 50 cent mine” that was about to get the “green light” from Trump’s EPA, and that one has done quite well so far — that was Midas Gold, which I wrote about back when they started […]
Alpha Contracts! That’s what’s being teased by the Agora Financial folks these days, all as part of a pitch for Zachary Scheidt’s Contract Income Alert. We haven’t covered this particular letter before, but have covered a few income-oriented pitches by Zach Scheidt for his other letters over the years, mostly talking up dividend-paying stocks and […]
Today’s article is a lightly updated revision of one that appeared on November 3, 2016, when an earlier “pre-election” version of the same ad was running. The hints about individual stocks are the same in the ad today, as is much of the rest of the language, though back then it was an urgent “pre-election” […]
Gumshoe readers wanna know: What’s a “Liberty Voucher?” And you can see why — inspired by the success of the ads that tease us about “Freedom Checks” or “Trump Bonus Checks”, this one from Nilus Mattive is all about getting your attention with the idea that those who don’t have enough cash flow to retire […]
This article originally ran as part of the Friday File for the Irregulars on January 12. It has not been updated or revised since then, though I’ve left the original reader comments appended and have also added an extra update comment at the bottom of the article. –As Published on 1/12/18– I’ve been working on […]
The number of questions about this one is going off the charts, so I’ll look into it for you — even though it’s related to not one but two bubblicious sectors that are designed for the manipulation of investors, so I might get a little grumpy. Bear with me. Here’s a little tantalizer from the […]
own money and re-positioned it to take advantage of this move. He makes reference to Trump doing something like that in the 80’s for $500,000 that he turned into 2,000,000 but it will be nothing like the scale that this will be on. He’s claiming that this may occur as soon as May 2, or […]
You know, I expect, that there’s no secret trove of “programs” where you can “sign up” and get a free check in the mail every month. But still, the notion that there’s “hidden income” out there is tempting… the newsletter promoters know that many of us are worried about income, or about not getting enough […]
This article was originally published on January 16 — the teaser pitch in question is still being actively sent and we’re still getting questions about it, so we re-publish it here for your information. It has not been updated or revised, the stock rose sharply in January around the time the ad started running, but […]
The latest ad from Teeka Tiwari for the Palm Beach Letter is pushing the idea that you can somehow collect some incredible monthly income with an “off the books” retirement income source… here’s how it’s introduced: “Now, For the First Time Ever, a Former Wall Street Hedge Fund Manager Reveals How You Can Unlock the […]
The talk of trade war with China is bringing the idea of Chinese mineral dominance back to the pages of investment teaser ads… we’ve seen several in the last week or two that focus on rare earths, where China remains dominant and might have some extra negotiating leverage in trade disputes, and this latest pitch […]